MARKET

PBYI

PBYI

Puma Biotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.91
-0.46
-4.39%
Closed 18:19 09/21 EDT
OPEN
10.16
PREV CLOSE
10.36
HIGH
10.17
LOW
9.71
VOLUME
621.74K
TURNOVER
--
52 WEEK HIGH
15.00
52 WEEK LOW
5.50
MARKET CAP
393.00M
P/E (TTM)
-9.2830
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Puma Biotechnology CEO Alan Auerbach will provide a company overview at the virtual H.C. Wainwright Global Conference on September 15, 2020.
Business Wire · 09/08 21:15
Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 15:31
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer
MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada. NERLYNX was
GlobeNewswire · 09/03 21:15
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Business Wire · 08/19 21:10
Puma Biotech announces new data on strategies to improve tolerability of neratinib
Puma Biotechnology (PBYI) reports positive preliminary results from an open-label Phase 2 clinical trial, CONTROL, evaluating certain approaches to mitigating diarrheal toxicity associated with breast cancer med neratinib, the most
Seekingalpha · 08/19 20:41
Puma Bio: A Contrarian Investment That Requires Patience
Puma Biotechnology recently reported their Q2 earnings that revealed a huge beat on EPS and revenue, but Puma is still struggling to surpass their Q4 2018 numbers.NERLYNX commercial data shows that physicians are employing the dose-escalation strategy to help improve tolerability and discontinuations.Despite some evidence of commercial progress, the stock continues to trade around a discounted 2x price-to-sales.I still see PBYI as a great contrarian investment that will require some patience and optimism in order to reap the benefits.
Seekingalpha · 08/17 10:16
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
On August 10, 2020, Puma Biotechnology reported the approval of inducement awards under Nasdaq Listing Rule 5635(c)(4).
Business Wire · 08/10 21:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PBYI stock price target is 11.67 with a high estimate of 16.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 215
Institutional Holdings: 40.93M
% Owned: 103.16%
Shares Outstanding: 39.68M
TypeInstitutionsShares
Increased
44
4.37M
New
51
-2.99M
Decreased
36
4.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Chief Executive Officer/President/Director
Alan Auerbach
Chief Financial Officer
Maximo Nougues
Senior Vice President
Douglas Hunt
Chief Scientific Officer
Richard Bryce
Lead Director/Independent Director
Jay Moyes
Director
Brian Stuglik
Independent Director
Ann Miller
Independent Director
Michael Miller
Independent Director
Hugh O Dowd
Independent Director
Adrian Senderowicz
Independent Director
Troy Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average PBYI stock price target is 11.67 with a high estimate of 16.00 and a low estimate of 6.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Puma Biotechnology Inc stock information, including NASDAQ:PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.